Edgewise Therapeutics Announces Positive Two-Year Topline Results From the Arch Open Label Trial of Sevasemten (Edg-5506) in Adults With Becker Muscular Dystrophy (Becker)
Edgewise Therapeutics宣布针对成年贝克尔肌肉萎缩症(贝克尔)的Sevasemten(Edg-5506)的Arch Open Label试验为期两年的阳性Topline结果